pyridoxamine has been researched along with Atheroma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J | 2 |
| Tao, H | 2 |
| Yancey, PG | 2 |
| Leuthner, Z | 2 |
| May-Zhang, LS | 2 |
| Jung, JY | 2 |
| Zhang, Y | 2 |
| Ding, L | 2 |
| Amarnath, V | 2 |
| Liu, D | 2 |
| Collins, S | 2 |
| Davies, SS | 2 |
| Linton, MF | 2 |
1 other study available for pyridoxamine and Atheroma
| Article | Year |
|---|---|
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |